{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:06:14Z","timestamp":1787868374111,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,8]]},"DOI":"10.7759\/cureus.31273","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T05:32:19Z","timestamp":1667971939000},"source":"Crossref","is-referenced-by-count":3,"title":["Can Alzheimer's Disease Be Secondary to Type-2 Diabetes Mellitus?"],"prefix":"10.7759","author":[{"given":"Vani","family":"Jangra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeshnu","family":"Tople","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18362","article-title":"The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer's disease","volume":"13","author":"Hobday AL","year":"2021","unstructured":"Hobday AL, Parmar MS. The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer's disease. Cureus. 2021, 13:e18362. 10.7759\/cureus.18362","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2019.12.028","article-title":"Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators","volume":"27","author":"Jayaraj RL","year":"2020","unstructured":"Jayaraj RL, Azimullah S, Beiram R. Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators. Saudi J Biol Sci. 2020, 27:736-50. 10.1016\/j.sjbs.2019.12.028","journal-title":"Saudi J Biol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19811","article-title":"Association of Alzheimer's disease and insulin resistance in King Abdulaziz Medical City, Jeddah","volume":"13","author":"Faqih NT","year":"2021","unstructured":"Faqih NT, Ashoor AF, Alshaikh SA, Maglan AF, Jastaniah N. Association of Alzheimer's disease and insulin resistance in King Abdulaziz Medical City, Jeddah. Cureus. 2021, 13:e19811. 10.7759\/cureus.19811","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052687","article-title":"Alzheimer's disease as Type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes","volume":"23","author":"Michailidis M","year":"2022","unstructured":"Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V. Alzheimer's disease as Type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes. Int J Mol Sci. 2022, 23:2687. 10.3390\/ijms23052687","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S30621","article-title":"Heart disease as a risk factor for dementia","volume":"5","author":"Justin BN","year":"2013","unstructured":"Justin BN, Turek M, Hakim AM. Heart disease as a risk factor for dementia. Clin Epidemiol. 2013, 5:135-45. 10.2147\/CLEP.S30621","journal-title":"Clin Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26162","article-title":"Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study","volume":"9","author":"Pegueroles J","year":"2018","unstructured":"Pegueroles J, Jim\u00e9nez A, Vilaplana E, et al.. Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget. 2018, 9:34691-8. 10.18632\/oncotarget.26162","journal-title":"Oncotarget"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000094586","article-title":"Obesity, abdominal obesity and Alzheimer disease","volume":"22","author":"Razay G","year":"2006","unstructured":"Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord. 2006, 22:173-6. 10.1159\/000094586","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38446.466238.E0","article-title":"Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study","volume":"330","author":"Whitmer RA","year":"2005","unstructured":"Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005, 330:1360. 10.1136\/bmj.38446.466238.E0","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00508","article-title":"Obesity as a risk factor for Alzheimer's disease: implication of leptin and glutamate","volume":"13","author":"Lloret A","year":"2019","unstructured":"Lloret A, Monllor P, Esteve D, Cervera-Ferri A, Lloret MA. Obesity as a risk factor for Alzheimer's disease: implication of leptin and glutamate. Front Neurosci. 2019, 13:508. 10.3389\/fnins.2019.00508","journal-title":"Front Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12807","article-title":"Impact of diabetes on cognitive function and brain structure","volume":"1353","author":"Moheet A","year":"2015","unstructured":"Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015, 1353:60-71. 10.1111\/nyas.12807","journal-title":"Ann N Y Acad Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108115","article-title":"Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease","volume":"171","author":"Mejido DC","year":"2020","unstructured":"Mejido DC, Peny JA, Vieira MN, Ferreira ST, De Felice FG. Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. Neuropharmacology. 2020, 171:108115. 10.1016\/j.neuropharm.2020.108115","journal-title":"Neuropharmacology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from Alzheimer's disease","volume":"430","author":"Mattson MP","year":"2004","unstructured":"Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004, 430:631-9. 10.1038\/nature02621","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113306","article-title":"Type 2 diabetes mellitus and Alzheimer's disease: role of insulin signalling and therapeutic implications","volume":"19","author":"Tumminia A","year":"2018","unstructured":"Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: role of insulin signalling and therapeutic implications. Int J Mol Sci. 2018, 19:3306. 10.3390\/ijms19113306","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00146","article-title":"Modifiable risk factors for Alzheimer's disease","volume":"11","author":"Edwards Iii GA","year":"2019","unstructured":"Edwards Iii GA, Gamez N, Escobedo G Jr, Calderon O, Moreno-Gonzalez I. Modifiable risk factors for Alzheimer's disease. Front Aging Neurosci. 2019, 11:146. 10.3389\/fnagi.2019.00146","journal-title":"Front Aging Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2017.5060","article-title":"The relationship between cerebral vasoreactivity and post-concussive symptom severity","volume":"34","author":"Albalawi T","year":"2017","unstructured":"Albalawi T, Hamner JW, Lapointe M, Meehan WP Rd, Tan CO. The relationship between cerebral vasoreactivity and post-concussive symptom severity. J Neurotrauma. 2017, 34:2700-5. 10.1089\/neu.2017.5060","journal-title":"J Neurotrauma"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317557","article-title":"Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia","volume":"90","author":"Graham NS","year":"2019","unstructured":"Graham NS, Sharp DJ. Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. J Neurol Neurosurg Psychiatry. 2019, 90:1221-33. 10.1136\/jnnp-2017-317557","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2174\/1871527320666210212114116","article-title":"Cellular and molecular mechanisms of dementia: decoding the causal link of diabetes mellitus in Alzheimer's disease","volume":"20","author":"Rasool M","year":"2021","unstructured":"Rasool M, Malik A, Waquar S, et al.. Cellular and molecular mechanisms of dementia: decoding the causal link of diabetes mellitus in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2021, 20:602-12. 10.2174\/1871527320666210212114116","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003211","article-title":"Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides","volume":"9","author":"Wu C","year":"2013","unstructured":"Wu C, Shea JE. Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides. PLoS Comput Biol. 2013, 9:e1003211. 10.1371\/journal.pcbi.1003211","journal-title":"PLoS Comput Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7762\/cnr.2018.7.4.229","article-title":"Diabetes and Alzheimer's disease: mechanisms and nutritional aspects","volume":"7","author":"Lee HJ","year":"2018","unstructured":"Lee HJ, Seo HI, Cha HY, Yang YJ, Kwon SH, Yang SJ. Diabetes and Alzheimer's disease: mechanisms and nutritional aspects. Clin Nutr Res. 2018, 7:229-40. 10.7762\/cnr.2018.7.4.229","journal-title":"Clin Nutr Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka MT","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, et al.. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14:388-405. 10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066397","article-title":"Long-term effect of diabetes and its treatment on cognitive function","volume":"356","author":"Jacobson AM","year":"2007","unstructured":"Jacobson AM, Musen G, Ryan CM, et al.. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007, 356:1842-52. 10.1056\/NEJMoa066397","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"\u0141abuzek K","year":"2010","unstructured":"\u0141abuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopie\u0144 B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep\r\n. 2010, 62:956-65. 10.1016\/s1734-1140(10)70357-1","journal-title":"Pharmacol Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2016.08.013","article-title":"Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction","volume":"347","author":"Chiang MC","year":"2016","unstructured":"Chiang MC, Cheng YC, Chen SJ, Yen CH, Huang RN. Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction. Exp Cell Res. 2016, 347:322-31. 10.1016\/j.yexcr.2016.08.013","journal-title":"Exp Cell Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.742586","article-title":"Metformin use and cognitive function in older adults with type 2 diabetes following a Mediterranean diet intervention","volume":"8","author":"Soldevila-Domenech N","year":"2021","unstructured":"Soldevila-Domenech N, Cuenca-Royo A, Babio N, et al.. Metformin use and cognitive function in older adults with type 2 diabetes following a Mediterranean diet intervention. Front Nutr. 2021, 8:742586. 10.3389\/fnut.2021.742586","journal-title":"Front Nutr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.09.030","article-title":"Glimepiride protects neurons against amyloid-\u03b2-induced synapse damage","volume":"101","author":"Osborne C","year":"2016","unstructured":"Osborne C, West E, Nolan W, McHale-Owen H, Williams A, Bate C. Glimepiride protects neurons against amyloid-\u03b2-induced synapse damage. Neuropharmacology. 2016, 101:225-36. 10.1016\/j.neuropharm.2015.09.030","journal-title":"Neuropharmacology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork SC","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015, 4:718-31. 10.1016\/j.molmet.2015.07.008","journal-title":"Mol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0593-3","article-title":"Effects of intranasal insulin as an enhancer of fear extinction: a randomized, double-blind, placebo-controlled experimental study","volume":"45","author":"Ferreira de S\u00e1 DS","year":"2020","unstructured":"Ferreira de S\u00e1 DS, R\u00f6mer S, Br\u00fcckner AH, Issler T, Hauck A, Michael T. Effects of intranasal insulin as an enhancer of fear extinction: a randomized, double-blind, placebo-controlled experimental study. Neuropsychopharmacology. 2020, 45:753-60. 10.1038\/s41386-019-0593-3","journal-title":"Neuropsychopharmacology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2005.01.008","article-title":"The role of insulin receptor signaling in the brain","volume":"16","author":"Plum L","year":"2005","unstructured":"Plum L, Schubert M, Br\u00fcning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005, 16:59-65. 10.1016\/j.tem.2005.01.008","journal-title":"Trends Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: a pilot clinical trial","volume":"57","author":"Craft S","year":"2017","unstructured":"Craft S, Claxton A, Baker LD, et al.. Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: a pilot clinical trial. J Alzheimers Dis. 2017, 57:1325-34. 10.3233\/JAD-161256","journal-title":"J Alzheimers Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2174\/156720507780362137","article-title":"Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment","volume":"4","author":"Craft S","year":"2007","unstructured":"Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007, 4:147-52. 10.2174\/156720507780362137","journal-title":"Curr Alzheimer Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold SE","year":"2018","unstructured":"Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al.. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018, 14:168-81. 10.1038\/nrneurol.2017.185","journal-title":"Nat Rev Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1740","article-title":"Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction","volume":"33","author":"Duning T","year":"2010","unstructured":"Duning T, van den Heuvel I, Dickmann A, et al.. Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction. Diabetes Care. 2010, 33:639-44. 10.2337\/dc09-1740","journal-title":"Diabetes Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.08.008","article-title":"Insulin, cognition, and dementia","volume":"719","author":"Cholerton B","year":"2013","unstructured":"Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol. 2013, 719:170-9. 10.1016\/j.ejphar.2013.08.008","journal-title":"Eur J Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1589-15.2015","article-title":"An obesity-predisposing variant of the FTO gene regulates D2R-dependent reward learning","volume":"35","author":"Sevgi M","year":"2015","unstructured":"Sevgi M, Rigoux L, K\u00fchn AB, et al.. An obesity-predisposing variant of the FTO gene regulates D2R-dependent reward learning. J Neurosci. 2015, 35:12584-92. 10.1523\/JNEUROSCI.1589-15.2015","journal-title":"J Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-7634(00)00040-3","article-title":"Insulin receptors and insulin action in the brain: review and clinical implications","volume":"24","author":"Schulingkamp RJ","year":"2000","unstructured":"Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev. 2000, 24:855-72. 10.1016\/s0149-7634(00)00040-3","journal-title":"Neurosci Biobehav Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.173","article-title":"Impaired insulin action in the human brain: causes and metabolic consequences","volume":"11","author":"Heni M","year":"2015","unstructured":"Heni M, Kullmann S, Preissl H, Fritsche A, H\u00e4ring HU. Impaired insulin action in the human brain: causes and metabolic consequences. Nat Rev Endocrinol. 2015, 11:701-11. 10.1038\/nrendo.2015.173","journal-title":"Nat Rev Endocrinol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03830.x","article-title":"Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?","volume":"71","author":"Akter K","year":"2011","unstructured":"Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br J Clin Pharmacol. 2011, 71:365-76. 10.1111\/j.1365-2125.2010.03830.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/116678-can-alzheimers-disease-be-secondary-to-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:45Z","timestamp":1707507705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/116678-can-alzheimers-disease-be-secondary-to-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.31273","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,8]]}}}